Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Lizhu Pharmaceutical's isosorbide mononitrate tablets, under the Jiankangyuan Group, have passed the review and are used to treat coronary heart disease.
Published Time：
2022-07-29
On the evening of July 27, Joincare Pharmaceutical Group Industry Co., Ltd. (Healthy Yuan, 600380.SH) announced that its holding subsidiary, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory, received the "Drug Supplement Application Approval Notification" issued by the National Medical Products Administration. The isosorbide mononitrate tablets produced by Lizhu Pharmaceutical Factory have passed the consistency evaluation of quality and efficacy of generic drugs.
Isosorbide mononitrate tablets are cardiovascular drugs. In China, they are national essential medicines and are Class A varieties in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog" (Medical Insurance [2021] No. 50). This drug is mainly used for the long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; and in combination with digitalis and/or diuretics to treat chronic congestive heart failure.
In the Chinese market, a total of 18 companies hold production licenses for isosorbide mononitrate tablets. To date, including Lizhu Pharmaceutical Factory, a total of 6 companies have passed the consistency evaluation for this product. The sales and demand for isosorbide mononitrate tablets at retail terminals are very considerable. According to IQVIA's sample statistics and estimated data, the terminal sales of isosorbide mononitrate oral preparations in China in 2021 were approximately RMB 1.479 billion, and the sales revenue of Lizhu Pharmaceutical Factory's isosorbide mononitrate tablets in 2021 was approximately RMB 15.8651 million.
As of the date of Healthy Yuan's announcement, the cumulative direct R&D expenses invested in the consistency evaluation of isosorbide mononitrate tablets were approximately RMB 7.5261 million. Passing the consistency evaluation will help improve the market competitiveness of this drug.
According to publicly available information, in recent years, Healthy Yuan has firmly implemented a dual-drive strategy of innovation and high-barrier complex preparations, taking unmet clinical needs as the foothold for innovative R&D. Through continuously increasing R&D investment, actively introducing senior domestic and foreign experts and innovative talents, and overseas strategic alliances, it focuses on the construction of high-barrier complex preparation technology platforms such as inhalation administration, antibody technology, sustained-release microspheres, and lipid microemulsions, continuously improving its R&D competitiveness. In 2021, Healthy Yuan's R&D expenses totaled RMB 1.397 billion, a year-on-year increase of 30.36%. Especially in the inhalation preparation field, where Healthy Yuan has focused its efforts, several key products are leading the evaluation list, accelerating the process of domestic substitution.
Healthy Yuan (600380.SH) has a good moat in terms of industry competitiveness. In the past 90 days, 5 institutions have given ratings, with 3 buy ratings and 2 increase holdings ratings.
Source: Cinda Online
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.